Immunovant Files 8-K on Shareholder Vote Matters
Ticker: IMVT · Form: 8-K · Filed: Aug 28, 2025 · CIK: 1764013
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, sec-filing
Related Tickers: IMVT
TL;DR
IMVT filed an 8-K for a shareholder vote on 8/27.
AI Summary
Immunovant, Inc. filed an 8-K on August 28, 2025, reporting on a submission of matters to a vote of security holders that occurred on August 27, 2025. The company, incorporated in Delaware, is involved in biological products and is headquartered in New York, NY.
Why It Matters
This filing indicates a formal process where Immunovant's security holders are being asked to vote on specific company matters, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- Immunovant, Inc. (company) — Registrant
- August 27, 2025 (date) — Date of earliest event reported
- August 28, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- New York, NY (location) — Address of principal executive offices
FAQ
What specific matters were submitted for a vote of Immunovant's security holders on August 27, 2025?
The filing does not specify the exact matters submitted for a vote; it only reports that such a submission occurred.
When did Immunovant, Inc. file this Form 8-K with the SEC?
Immunovant, Inc. filed this Form 8-K on August 28, 2025.
What is Immunovant, Inc.'s primary business sector?
Immunovant, Inc. is in the Biological Products sector, specifically SIC code 2836.
Where is Immunovant, Inc. headquartered?
Immunovant, Inc. is headquartered at 320 West 37th Street, New York, NY 10018.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 666 words · 3 min read · ~2 pages · Grade level 15.7 · Accepted 2025-08-28 16:13:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Sto
Filing Documents
- imvt-20250827.htm (8-K) — 38KB
- 0001764013-25-000132.txt ( ) — 150KB
- imvt-20250827.xsd (EX-101.SCH) — 2KB
- imvt-20250827_lab.xml (EX-101.LAB) — 21KB
- imvt-20250827_pre.xml (EX-101.PRE) — 12KB
- imvt-20250827_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 27, 2025, Immunovant, Inc. ( " Immunovant " ) held its 2025 Annual Meeting of Stockholders (the " Annual Meeting " ). There were 165,885,480 shares of common stock and Series A preferred stock represented at the Annual Meeting by valid proxies or voted at the Annual Meeting, which was approximately 97% of the shares of common stock and Series A preferred stock entitled to vote at the Annual Meeting. At the Annual Meeting, Immunovant's stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in Immunovant's definitive proxy statement for the Annual Meeting (the " Proxy Statement " ), which was filed with the Securities and Exchange Commission on July 9, 2025. Proposal 1 – Election of Directors Jacob Bauer, Douglas Hughes and Robert Susman were each elected to serve as a member of Immunovant's Board of Directors (the " Board " ), until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Jacob Bauer 152,051,231 8,193,169 5,641,080 Douglas Hughes 143,417,281 16,827,119 5,641,080 Robert Susman 159,234,780 1,009,620 5,641,080 Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2026, by the following votes: Votes For Votes Against Votes Abstain 165,422,634 7,237 455,609 Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant ' s named executive officers, as disclosed in the Proxy Statement, including the compensation tabl
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Tiago Girao Tiago Girao Chief Financial Officer Date: August 28, 2025